{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T00:26:17Z","timestamp":1686615977956},"reference-count":80,"publisher":"Georg Thieme Verlag KG","issue":"06","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Semin Thromb Hemost"],"published-print":{"date-parts":[[2021,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The holy grail of anticoagulation in patients with intracardiac devices, such as mechanical heart valves (MHVs) and left ventricular assist devices (LVADs), comprises safe prevention of thrombosis without interrupting normal hemostasis. Device-induced thrombosis and anticoagulant-related bleeding problems are dreaded complications that may cause a significantly reduced quality of life and increased morbidity and mortality. Vitamin K antagonists are the current standard for oral anticoagulation therapy in patients with MHVs and LVADs. Even within the therapeutic range, hemorrhage is the primary complication of these drugs, which emphasizes the need for safer anticoagulants for the prevention of device-induced thrombosis. Device-induced thrombosis is a complex multifactorial phenomenon that likely requires anticoagulant therapy targeting multiple pathways. Here, we review the preclinical and clinical data describing the efficacy of a variety of anticoagulants as thromboprophylaxis after implantation of intracardiac devices.<\/jats:p>","DOI":"10.1055\/s-0041-1722846","type":"journal-article","created":{"date-parts":[[2021,5,31]],"date-time":"2021-05-31T23:35:06Z","timestamp":1622504106000},"page":"724-734","source":"Crossref","is-referenced-by-count":3,"title":["Alternatives for Vitamin K Antagonists as Thromboprophylaxis for Mechanical Heart Valves and Mechanical Circulatory Support Devices: A Systematic Review"],"prefix":"10.1055","volume":"47","author":[{"given":"Omayra C.D.","family":"Liesdek","sequence":"additional","affiliation":[{"name":"Department of Cardiothoracic Surgery, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands"},{"name":"Van Creveldkliniek, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rolf T.","family":"Urbanus","sequence":"additional","affiliation":[{"name":"Van Creveldkliniek, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda M.","family":"de Heer","sequence":"additional","affiliation":[{"name":"Department of Cardiothoracic Surgery, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathelijn","family":"Fischer","sequence":"additional","affiliation":[{"name":"Van Creveldkliniek, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Willem J.L.","family":"Suyker","sequence":"additional","affiliation":[{"name":"Department of Cardiothoracic Surgery, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger E.G.","family":"Schutgens","sequence":"additional","affiliation":[{"name":"Van Creveldkliniek, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2021,5,31]]},"reference":[{"issue":"02","key":"ref1","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1161\/01.CIR.89.2.635","article-title":"Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses","volume":"89","author":"S C Cannegieter","year":"1994","journal-title":"Circulation"},{"issue":"02","key":"ref2","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.thromres.2014.06.007","article-title":"Thromboembolism, major bleeding and mortality in patients with mechanical heart valves- a population-based cohort study","volume":"134","author":"A Labaf","year":"2014","journal-title":"Thromb Res"},{"issue":"06","key":"ref3","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1111\/jth.12948","article-title":"Antithrombotic therapy for left ventricular assist devices in adults: a systematic review","volume":"13","author":"L M Baumann Kreuziger","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"12","key":"ref4","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/j.healun.2015.10.024","article-title":"Pump thrombosis in the Thoratec HeartMate II device: an update analysis of the INTERMACS registry","volume":"34","author":"J K Kirklin","year":"2015","journal-title":"J Heart Lung Transplant"},{"issue":"23","key":"ref5","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1056\/NEJMoa0909938","article-title":"Advanced heart failure treated with continuous-flow left ventricular assist device","volume":"361","author":"M S Slaughter","year":"2009","journal-title":"N Engl J Med"},{"issue":"15","key":"ref6","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1056\/NEJMoa1800866","article-title":"Two-year outcomes with a magnetically levitated cardiac pump in heart failure","volume":"378","author":"M R Mehra","year":"2018","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.healun.2010.01.011","article-title":"Clinical management of continuous-flow left ventricular assist devices in advanced heart failure","volume":"29","author":"M S Slaughter","year":"2010","journal-title":"J Heart Lung Transplant"},{"issue":"25","key":"ref8","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.1161\/CIRCULATIONAHA.111.058412","article-title":"Use of an intrapericardial, continuous-flow, centrifugal pump in patients awaiting heart transplantation","volume":"125","author":"K D Aaronson","year":"2012","journal-title":"Circulation"},{"issue":"05","key":"ref9","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1056\/NEJMoa1602954","article-title":"Intrapericardial left ventricular assist device for advanced heart failure","volume":"376","author":"J G Rogers","year":"2017","journal-title":"N Engl J Med"},{"issue":"10","key":"ref10","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/S0002-9149(00)01166-8","article-title":"Prediction of thrombus-related mechanical prosthetic valve dysfunction using transesophageal echocardiography","volume":"86","author":"S S Lin","year":"2000","journal-title":"Am J Cardiol"},{"issue":"24","key":"ref11","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1016\/j.jacc.2016.09.958","article-title":"Prosthetic heart valve thrombosis","volume":"68","author":"G D Dangas","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"05","key":"ref12","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1586\/17434440.2016.1166051","article-title":"Using medical imaging for the detection of adverse events (\u201cincidents\u201d) during the utilization of left ventricular assist devices in adult patients with advanced heart failure","volume":"13","author":"F Kaufmann","year":"2016","journal-title":"Expert Rev Med Devices"},{"issue":"02","key":"ref13","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.jacc.2017.03.011","article-title":"2017 AHA\/ACC Focused Update of the 2014 AHA\/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"70","author":"R A Nishimura","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"36","key":"ref14","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1093\/eurheartj\/ehx391","article-title":"2017 ESC\/EACTS Guidelines for the management of valvular heart disease","volume":"38","author":"H Baumgartner","year":"2017","journal-title":"Eur Heart J"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"e44S","DOI":"10.1378\/chest.11-2292","article-title":"Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"W Ageno","year":"2012","journal-title":"Chest"},{"issue":"04","key":"ref16","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/S0735-1097(00)00834-2","article-title":"Outcomes 15 years after valve replacement with a mechanical versus a bioprosthetic valve: final report of the Veterans Affairs randomized trial","volume":"36","author":"K Hammermeister","year":"2000","journal-title":"J Am Coll Cardiol"},{"issue":"02","key":"ref17","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.athoracsur.2018.11.011","article-title":"The Society of Thoracic Surgeons Intermacs Database Annual Report: evolving indications, outcomes, and scientific partnerships","volume":"107","author":"R L Kormos","year":"2019","journal-title":"Ann Thorac Surg"},{"issue":"01","key":"ref18","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1093\/ejcts\/ezt228","article-title":"Is anti-platelet therapy needed in continuous flow left ventricular assist device patients? A single-centre experience","volume":"45","author":"P Y Litzler","year":"2014","journal-title":"Eur J Cardiothorac Surg"},{"issue":"05","key":"ref19","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1111\/jocs.12158","article-title":"Clinical differences between continuous flow ventricular assist devices: a comparison between HeartMate II and HeartWare HVAD","volume":"28","author":"S D Lalonde","year":"2013","journal-title":"J Card Surg"},{"issue":"12","key":"ref20","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1016\/j.cjca.2014.07.746","article-title":"Multicentre Canadian experience with the HeartWare ventricular assist device: concerns about adverse neurological outcomes","volume":"30","author":"J Bashir","year":"2014","journal-title":"Can J Cardiol"},{"issue":"03","key":"ref21","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1097\/MAT.0000000000000074","article-title":"Stroke while on long-term left ventricular assist device support: incidence, outcome, and predictors","volume":"60","author":"J A Morgan","year":"2014","journal-title":"ASAIO J"},{"issue":"02","key":"ref22","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.athoracsur.2015.02.094","article-title":"Stroke after left ventricular assist device implantation: outcomes in the continuous-flow era","volume":"100","author":"L Harvey","year":"2015","journal-title":"Ann Thorac Surg"},{"issue":"06","key":"ref23","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1016\/j.athoracsur.2014.02.041","article-title":"Hemolysis, pump thrombus, and neurologic events in continuous-flow left ventricular assist device recipients","volume":"97","author":"B A Whitson","year":"2014","journal-title":"Ann Thorac Surg"},{"issue":"10","key":"ref24","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.jchf.2015.05.011","article-title":"The HVAD left ventricular assist device: risk factors for neurological events and risk mitigation strategies","volume":"3","author":"J J Teuteberg","year":"2015","journal-title":"JACC Heart Fail"},{"issue":"06","key":"ref25","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.healun.2016.12.010","article-title":"Risk factors, mortality, and timing of ischemic and hemorrhagic stroke with left ventricular assist devices","volume":"36","author":"J A Frontera","year":"2017","journal-title":"J Heart Lung Transplant"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S0140-6736(96)03487-3","article-title":"Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial","volume":"348","year":"1996","journal-title":"Lancet"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.2741\/4462","article-title":"Heparin and anticoagulation","volume":"21","author":"A Onishi","year":"2016","journal-title":"Front Biosci"},{"issue":"01","key":"ref28","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.jtcvs.2018.06.089","article-title":"How to bridge? Management of anticoagulation in patients with mechanical heart valves undergoing noncardiac surgical procedures","volume":"158","author":"C W Tan","year":"2019","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"01","key":"ref29","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/j.1527-3466.2002.tb00081.x","article-title":"Fondaparinux, a synthetic pentasaccharide: the first in a new class of antithrombotic agents - the selective factor Xa inhibitors","volume":"20","author":"K A Bauer","year":"2002","journal-title":"Cardiovasc Drug Rev"},{"issue":"02","key":"ref30","first-page":"245","article-title":"Fondaparinux and enoxaparin in comparison to unfractionated heparin in preventing thrombus formation on mechanical heart valves in an ex vivo rabbit model","volume":"90","author":"A Schlitt","year":"2003","journal-title":"Thromb Haemost"},{"issue":"04","key":"ref31","doi-asserted-by":"crossref","first-page":"198","DOI":"10.5414\/CPP46198","article-title":"Use of fondaparinux as an anticoagulant during hemodialysis: a preliminary study","volume":"46","author":"K I Sombolos","year":"2008","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"06","key":"ref32","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1160\/TH07-07-0444","article-title":"Use of the pentasaccharide fondaparinux as an anticoagulant during haemodialysis","volume":"98","author":"R M Kalicki","year":"2007","journal-title":"Thromb Haemost"},{"issue":"05","key":"ref33","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/aor.12002","article-title":"Anticoagulation with fondaparinux for hemodiafiltration in patients with heparin-induced thrombocytopenia: dose-finding study and safety evaluation","volume":"37","author":"E Mahieu","year":"2013","journal-title":"Artif Organs"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.ijcard.2016.03.056","article-title":"Specific antidotes against direct oral anticoagulants: A comprehensive review of clinical trials data","volume":"214","author":"R Tummala","year":"2016","journal-title":"Int J Cardiol"},{"issue":"01","key":"ref35","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/S0022-5223(19)38486-7","article-title":"Antiplatelet drugs and the incidence of thromboembolic complications of the St. Jude Medical aortic prosthesis in patients with rheumatic heart disease","volume":"91","author":"P A Ribeiro","year":"1986","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"04","key":"ref36","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/S0022-5223(19)35872-6","article-title":"Comparative study of warfarin versus antiplatelet therapy in patients with a St. Jude Medical valve in the aortic position","volume":"92","author":"R S Hartz","year":"1986","journal-title":"J Thorac Cardiovasc Surg"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0049-3848(02)00185-8","article-title":"Effects of combined therapy of clopidogrel and aspirin in preventing thrombus formation on mechanical heart valves in an ex vivo rabbit model","volume":"107","author":"A Schlitt","year":"2002","journal-title":"Thromb Res"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0049-3848(03)00143-9","article-title":"Clopidogrel and aspirin in the prevention of thromboembolic complications after mechanical aortic valve replacement (CAPTA)","volume":"109","author":"A Schlitt","year":"2003","journal-title":"Thromb Res"},{"issue":"01","key":"ref39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jss.2006.11.024","article-title":"A model of heterotopic aortic valve replacement for studying thromboembolism prophylaxis in mechanical valve prostheses","volume":"141","author":"S H McKellar","year":"2007","journal-title":"J Surg Res"},{"issue":"04","key":"ref40","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.jtcvs.2008.01.045","article-title":"Short- and long-term efficacy of aspirin and clopidogrel for thromboprophylaxis for mechanical heart valves: an in vivo study in swine","volume":"136","author":"S H McKellar","year":"2008","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"24","key":"ref41","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1016\/j.jacc.2018.03.535","article-title":"Anticoagulation and antiplatelet strategies After On-X mechanical aortic valve replacement","volume":"71","author":"J D Puskas","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"ref42","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1111\/j.1538-7836.2007.02748.x","article-title":"Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial","volume":"5","author":"B I Eriksson","year":"2007","journal-title":"J Thromb Haemost"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S0140-6736(07)61445-7","article-title":"Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial","volume":"370","author":"B I Eriksson","year":"2007","journal-title":"Lancet"},{"issue":"04","key":"ref44","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1160\/TH10-10-0679","article-title":"Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trial","volume":"105","author":"B I Eriksson","year":"2011","journal-title":"Thromb Haemost"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)60880-6","article-title":"Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial","volume":"372","author":"A K Kakkar","year":"2008","journal-title":"Lancet"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1016\/S0140-6736(09)60734-0","article-title":"Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial","volume":"373","author":"A G Turpie","year":"2009","journal-title":"Lancet"},{"issue":"26","key":"ref47","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1056\/NEJMoa076016","article-title":"Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty","volume":"358","author":"M R Lassen","year":"2008","journal-title":"N Engl J Med"},{"issue":"26","key":"ref48","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1056\/NEJMoa0800374","article-title":"Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty","volume":"358","author":"B I Eriksson","year":"2008","journal-title":"N Engl J Med"},{"issue":"24","key":"ref49","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa0906598","article-title":"Dabigatran versus warfarin in the treatment of acute venous thromboembolism","volume":"361","author":"S Schulman","year":"2009","journal-title":"N Engl J Med"},{"issue":"02","key":"ref50","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jvn.2011.03.002","article-title":"Review of an article: oral rivaroxaban for symptomatic venous thromboembolism. The EINSTEIN Investigators et al. N Engl J Med 2010; 363(26):2499-2510","volume":"29","author":"J D Nunnelee","year":"2011","journal-title":"J Vasc Nurs"},{"issue":"12","key":"ref51","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"S J Connolly","year":"2009","journal-title":"N Engl J Med"},{"issue":"04","key":"ref52","doi-asserted-by":"crossref","first-page":"533","DOI":"10.2217\/fca.12.26","article-title":"Rivaroxaban for stroke prevention in atrial fibrillation and secondary prevention in patients with a recent acute coronary syndrome","volume":"8","author":"I Ahrens","year":"2012","journal-title":"Future Cardiol"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4081\/itjm.2013.s8.1","article-title":"Pharmacology of new oral anticoagulants: mechanism of action, pharmacokinetics, pharmacodynamics","volume":"7","author":"L Masotti","year":"2013","journal-title":"Ital J Med"},{"issue":"02","key":"ref54","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s40268-019-0274-z","article-title":"Comparison of the new oral anticoagulants and warfarin in patients with atrial fibrillation and valvular heart disease: systematic review and meta-analysis","volume":"19","author":"Y de Souza Lima Bitar","year":"2019","journal-title":"Drugs R D"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"C T Ruff","year":"2014","journal-title":"Lancet"},{"issue":"06","key":"ref56","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1016\/j.jtcvs.2011.02.011","article-title":"Effectiveness of dabigatran etexilate for thromboprophylaxis of mechanical heart valves","volume":"141","author":"S H McKellar","year":"2011","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"03","key":"ref57","doi-asserted-by":"crossref","first-page":"150","DOI":"10.3109\/08941939.2011.616256","article-title":"Dabigatran versus warfarin after mechanical mitral valve replacement in the swine model","volume":"25","author":"J L Schomburg","year":"2012","journal-title":"J Invest Surg"},{"issue":"02","key":"ref58","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.jtcvs.2007.01.093","article-title":"Melagatran for thromboprophylaxis after mechanical valve implantation: results in a heterotopic porcine model","volume":"134","author":"J L Thompson","year":"2007","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"13","key":"ref59","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJMoa1300615","article-title":"Dabigatran versus warfarin in patients with mechanical heart valves","volume":"369","author":"J W Eikelboom","year":"2013","journal-title":"N Engl J Med"},{"issue":"01","key":"ref60","first-page":"20","article-title":"Dabigatran etexilate as second-line therapy in patients with a left ventricular assist device","volume":"56","author":"J V Terrovitis","year":"2015","journal-title":"Hellenic J Cardiol"},{"issue":"05","key":"ref61","doi-asserted-by":"crossref","first-page":"e003709","DOI":"10.1161\/CIRCHEARTFAILURE.116.003709","article-title":"Increased thromboembolic events with dabigatran compared with vitamin K antagonism in left ventricular assist device patients: a randomized controlled pilot trial","volume":"10","author":"M Andreas","year":"2017","journal-title":"Circ Heart Fail"},{"issue":"04","key":"ref62","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jacc.2013.07.104","article-title":"The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy)","volume":"63","author":"P A Reilly","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"ref63","first-page":"1074","article-title":"Relationship between international normalized ratio values, vitamin K-dependent clotting factor levels and in vivo prothrombin activation during the early and steady phases of oral anticoagulant treatment","volume":"87","author":"A D'Angelo","year":"2002","journal-title":"Haematologica"},{"issue":"02","key":"ref64","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1124\/dmd.107.019083","article-title":"The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans","volume":"36","author":"S Blech","year":"2008","journal-title":"Drug Metab Dispos"},{"issue":"03","key":"ref65","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.blre.2006.11.001","article-title":"Thrombin generation and fibrin clot structure","volume":"21","author":"A S Wolberg","year":"2007","journal-title":"Blood Rev"},{"issue":"01","key":"ref66","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1160\/TH13-12-1047","article-title":"Only high levels of dabigatran attenuate catheter thrombosis in vitro and in rabbits","volume":"112","author":"J W Yau","year":"2014","journal-title":"Thromb Haemost"},{"issue":"06","key":"ref67","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/j.thromres.2014.09.030","article-title":"Contact activation of blood coagulation on a defined kaolin\/collagen surface in a microfluidic assay","volume":"134","author":"S Zhu","year":"2014","journal-title":"Thromb Res"},{"issue":"05","key":"ref68","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1093\/ejcts\/ezt545","article-title":"Effectiveness of rivaroxaban for thromboprophylaxis of prosthetic heart valves in a porcine heterotopic valve model","volume":"45","author":"L E Greiten","year":"2014","journal-title":"Eur J Cardiothorac Surg"},{"issue":"05","key":"ref69","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1161\/ATVBAHA.116.308649","article-title":"Apixaban versus warfarin for mechanical heart valve thromboprophylaxis in a swine aortic heterotopic valve model","volume":"37","author":"P A Lester","year":"2017","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"05","key":"ref70","first-page":"710","article-title":"Development and evaluation of a swine model to assess the preclinical safety of mechanical heart valves","volume":"9","author":"J F Grehan","year":"2000","journal-title":"J Heart Valve Dis"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3389\/fcvm.2020.00087","article-title":"Reversal of bioprosthetic aortic valve thrombosis using rivaroxaban-a case report","volume":"7","author":"H Sharma","year":"2020","journal-title":"Front Cardiovasc Med"},{"issue":"07","key":"ref72","doi-asserted-by":"crossref","first-page":"e008481","DOI":"10.1161\/CIRCINTERVENTIONS.119.008481","article-title":"Reduced rivaroxaban dose versus dual antiplatelet therapy after left atrial appendage closure: ADRIFT a randomized pilot study","volume":"13","author":"G Duthoit","year":"2020","journal-title":"Circ Cardiovasc Interv"},{"issue":"17","key":"ref73","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1182\/blood-2017-04-569111","article-title":"Coagulation factor XII in thrombosis and inflammation","volume":"131","author":"C Maas","year":"2018","journal-title":"Blood"},{"issue":"13","key":"ref74","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1182\/blood-2013-12-540872","article-title":"Selective depletion of factor XI or factor XII with antisense oligonucleotides attenuates catheter thrombosis in rabbits","volume":"123","author":"J W Yau","year":"2014","journal-title":"Blood"},{"issue":"222","key":"ref75","doi-asserted-by":"crossref","first-page":"222ra17","DOI":"10.1126\/scitranslmed.3006804","article-title":"A factor XIIa inhibitory antibody provides thromboprotection in extracorporeal circulation without increasing bleeding risk","volume":"6","author":"M Larsson","year":"2014","journal-title":"Sci Transl Med"},{"issue":"02","key":"ref76","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/rth2.12309","article-title":"Antibody inhibition of contact factor XII reduces platelet deposition in a model of extracorporeal membrane oxygenator perfusion in nonhuman primates","volume":"4","author":"M Wallisch","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"issue":"03","key":"ref77","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1405760","article-title":"Factor XI antisense oligonucleotide for prevention of venous thrombosis","volume":"372","author":"H R B\u00fcller","year":"2015","journal-title":"N Engl J Med"},{"issue":"02","key":"ref78","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1001\/jama.2019.20687","article-title":"Effect of osocimab in preventing venous thromboembolism among patients undergoing knee arthroplasty: the FOXTROT randomized clinical trial","volume":"323","author":"J I Weitz","year":"2020","journal-title":"JAMA"},{"issue":"03","key":"ref79","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1160\/TH08-02-0103","article-title":"Interspecies differences in coagulation profile","volume":"100","author":"J M Siller-Matula","year":"2008","journal-title":"Thromb Haemost"},{"issue":"09","key":"ref80","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1182\/blood-2016-09-742262","article-title":"Factor XI deficiency is associated with lower risk for cardiovascular and venous thromboembolism events","volume":"129","author":"M Preis","year":"2017","journal-title":"Blood"}],"container-title":["Seminars in Thrombosis and Hemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0041-1722846.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T22:53:54Z","timestamp":1630536834000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0041-1722846"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,31]]},"references-count":80,"journal-issue":{"issue":"06","published-online":{"date-parts":[[2021,9,1]]},"published-print":{"date-parts":[[2021,9]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0041-1722846","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0094-6176","1098-9064"],"issn-type":[{"value":"0094-6176","type":"print"},{"value":"1098-9064","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,31]]}}}